Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04827875 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

A Phase 1 study, sponsored by AiViva BioPharma.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target

NCT04827875: Completed Phase 1 study, sponsored by AiViva BioPharma.

NCT04827875 is a Phase 1 study that has completed, run by AiViva BioPharma. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04827875, a Phase 1 study, has completed, sponsored by AiViva BioPharma.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target

Study Summary

To evaluate the saftye and effectiveness of AIV001 treatment on scar formation and/or keloid scar recurrence following keloidectomy.

Primary Outcome

Incidence of adverse events

Interventions

  • DRUG AIV001

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2021-06-23
Est. Completion 2022-12-15
Phase Phase 1
AiViva BioPharma

5 total trials

What the finished NCT04827875 record still lists

NCT04827875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 1 intervention - of which AIV001 is the first listed.

NCT04827875 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04827875 about?

NCT04827875 is a clinical study titled "Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy". To evaluate the saftye and effectiveness of AIV001 treatment on scar formation and/or keloid scar recurrence following keloidectomy.

What is the current status of trial NCT04827875?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-06-23. Estimated completion is 2022-12-15.

What interventions are being tested in trial NCT04827875?

The interventions under investigation include: AIV001 (DRUG).

Who is sponsoring clinical trial NCT04827875?

This trial is sponsored by AiViva BioPharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04827875's enrollment target sits among peer trials

25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-07-11

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT04701684 · started 2021-06-23 · NA

    WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

  • NCT04915508 · started 2021-06-23 · Phase 2

    Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

  • NCT05680987 · started 2021-06-23 · NA

    Retrograde Femoral Nail-Advanced Outcomes for Fixation of Distal Femur and Femoral Shaft Fractures

  • NCT04372108 · started 2021-06-24

    A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Source: ClinicalTrials.gov NCT04827875, the US trial registry maintained by the National Library of Medicine. NCT04827875 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.